Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making

Table 1 Defined requirements for the DA content

Target	Target definition
Target group	The DA should be designed for female previvors and survivors with pathogenic BRCA1 or BRCA2 mutations
Target decision	The addressed decision situation should be the choice of an individual preventive strategy
Decision-making-related target	The DA should help previvors and survivors make informed decisions and clarify their individual values and preferences
Information/content-related target	The DA should address the risks of breast cancer and ovarian cancer and present the respective preventive options, including their consequences. Existing data on lifetime and on age and time-related risks should be taken into account in order to facilitate the women’s risk perception within a foreseeable period of time
Needs-related target	The DA should fulfil the specific needs of the target group
Evidence-related target	The medical content should be based on the currently applicable German S3 and S2 guidelines and, where necessary, on additional data with a high level of evidence; preferably data with an expected level of evidence of IIb and higher (e.g. systematic reviews based on RCTs, meta-analyses, RCTs, high quality cohort studies)

BRCA1 and BRCA2: BReast CAncer genes 1 and 2; DA: decision aid; previvors: women with pathogenic BRCA1 or BRCA2 mutations without a personal history of cancer; survivors: women with pathogenic BRCA1 or BRCA2 mutations with a personal history of unilateral breast cancer; RCTs: randomised controlled trials; S3 guidelines: systematically elaborated evidence-based guidelines for medical recommendations, elaborated with all elements of systematic development (highest quality level); S2 guidelines: systematically elaborated evidence-based guidelines for medical recommendations (S2e)

ISSN: 1472-6947